Clinical-stage biotechnology company Tyra Biosciences Inc (Nasdaq:TYRA) announced on Tuesday the appointment of Doug Warner, MD as its new chief medical officer.

In this role Dr Warner will be responsible for managing the company's clinical portfolio and will serve as a key member of its executive management team.

Dr Warner served in roles of increasing responsibility for more than 18 years at Amgen. Most recently he was chief medical officer for eFFECTOR Therapeutics.

Dr Warner is the co-author of various peer-reviewed articles published in The Lancet, The Lancet Oncology and The Journal of Clinical Oncology.

Todd Harris, CEO of Tyra Biosciences, said: "TYRA is at an inflection point with three potentially best-in-class candidate medicines for oncology and a planned filing of an IND to support clinical development in achondroplasia later this year. Doug has successfully led programmes from the earliest stages of development to securing global registrations in major markets, and he brings with him significant global development expertise across both targeted oncology and bone diseases. His background is a perfect fit for TYRA today, and his proven leadership in guiding programs to registration will be invaluable as we look to deliver on the full promise of our precision medicines."